Hólyagrák: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• HER2 47
• PD-1 18
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• ERK 0
• MYC 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

2+ intézményből 2, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the COMPASS that guides cancer

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution 2 000 000 EUR· until 2030. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetics of Bladder Cancer Evolution. (Epi-BCE)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Görögország· EU contribution 197 264 EUR· until 2027. márc.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Development of Metastatic Organ-on-a-Chip for modelling the role of sex steroids in Bladder cancer metastasis to bone (DeMOBilise)

  University of Limerick· Limerick, Írország· EU contribution 328 495 EUR· until 2028. aug.· 2 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement (BRECISE)

  South East Technological University· Waterford, Írország· EU contribution 13 615 935 EUR· until 2029. dec.· 14 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours (IMPACT)

  Impact Biotech Ltd· Ness Tziona, Izrael· EU contribution 2 498 731 EUR· until 2026. nov.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC-BF

  The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer (QIandQD)

  Qlucore Ab· Lund, Svédország· EU contribution 2 491 650 EUR· until 2027. ápr.

• European Commission (Horizon Europe) · HORIZON-RIA

  ULTRA-FAST CHEMICAL ANALYSIS IMAGING WITH RAMAN (uCAIR)

  University of Limerick· Limerick, Írország· EU contribution 4 996 749 EUR· until 2027. dec.· 6 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  MULti-Tumour based prediction and manipulation of Immune Response (MULTIR)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 8 547 712 EUR· until 2027. dec.· 12 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  Photoacoustic imaging and artificial intelligence-based theranostic approach for cancer (PHIRE)

  Ospedale San Raffaele Srl· Milano, Olaszország· EU contribution 2 084 871 EUR· until 2026. dec.· 4 countries

9 of 9 running projects, newest first. Listed amounts together: 36,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 23
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 78
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 94
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 77
• Genome-Wide Association Study 18

• Proteomic Analysis of Sphingolipid Metabolic Enzymes with Risk of Bladder Cancer Incidence and Mortality in the Atherosclerosis Risk in Communities Study.

  Cancer Prev Res (Phila), 2026. okt.

• Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR-Altered Solid Tumors.

  Clin Cancer Res, 2026. szept.

• Using human proteomic and lipidomic to exploration drug target of bladder cancer.

  World J Urol, 2026. aug.

• Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation.

  J Proteome Res, 2026. aug.

• Pan-cancer multi-omics machine learning defines a lactylation-associated immune-excluded tumor state with proteomic and experimental corroboration.

  Comput Biol Chem, 2026. júl.

• MPOInt: An Epigenetics-Driven Workflow for Integrative Multi-Level Proteomics.

  J Proteome Res, 2026. jún.

• Evaluation of FASP for Mass Spectrometry-Based Untargeted Metabolomics Analysis of Urine Samples.

  J Proteome Res, 2026. jún.

• Violacein as a multitarget agent in bladder cancer cells.

  J Proteomics, 2026. jún.

• Integrating multi-omics and machine learning to decipher the molecular pathways of bisphenol a-associated lactylation-related genes driving bladder cancer.

  PLoS One, 2026. máj.

• Urinary Peptidomic Signatures Predict Overall and Progression-Free Survival in Bladder Cancer.

  Proteomics, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.